The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism who remain symptomatic despite use of H1 antihistamines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results